Scilex Holding Company Proceeds from Stock Options Exercised
Scilex Holding Company (SCLX) reported Proceeds from Stock Options Exercised of $21.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-14
- Scilex Holding Company proceeds from stock options exercised for the quarter ending 2025-12-31 was $6.00K, a 99.50% decline year-over-year.
- Scilex Holding Company proceeds from stock options exercised for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company proceeds from stock options exercised for the quarter ending 2025-06-30 was $17.00K, a 94.96% decline year-over-year.
- Scilex Holding Company proceeds from stock options exercised for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company proceeds from stock options exercised for fiscal 2025 was $23.00K, a 98.91% decline from fiscal 2024.
- Scilex Holding Company proceeds from stock options exercised for fiscal 2024 was $2.11M, a 86.17% increase from fiscal 2023.
- Scilex Holding Company proceeds from stock options exercised for fiscal 2023 was $1.14M, a 1082.29% increase from fiscal 2022.
- Scilex Holding Company proceeds from stock options exercised for fiscal 2022 was $96.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.00K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $6.00K derived: sum of 2 quarters · filed 2026-04-10 | $23.00K derived: sum of 3 quarters · filed 2026-08-14 | $23.00K 10-K · filed 2026-04-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $17.00K derived: sum of 2 quarters · filed 2026-08-14 | $17.00K 10-Q · filed 2025-11-14 | $1.22M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $17.00K 10-Q · filed 2026-08-14 | $1.22M derived: sum of 3 quarters · filed 2026-08-14 | $1.75M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-14 | $1.20M derived: sum of 2 quarters · filed 2026-04-10 | $1.73M derived: sum of 3 quarters · filed 2026-04-10 | $2.07M derived: sum of 4 quarters · filed 2026-04-10 |
| 2024-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $1.73M derived: sum of 2 quarters · filed 2026-04-10 | $2.07M derived: sum of 3 quarters · filed 2026-04-10 | $2.11M 10-K · filed 2026-04-10 |
| 2024-09-30 | $532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $869.00K derived: sum of 2 quarters · filed 2025-11-14 | $915.00K 10-Q · filed 2025-11-14 | $949.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $337.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $383.00K 10-Q · filed 2025-08-13 | $417.00K derived: sum of 3 quarters · filed 2025-08-13 | $775.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $46.00K 10-Q · filed 2025-05-14 | $80.00K derived: sum of 2 quarters · filed 2025-05-14 | $438.00K derived: sum of 3 quarters · filed 2025-05-14 | $1.18M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $392.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.14M derived: sum of 3 quarters · filed 2025-03-31 | $1.14M 10-K · filed 2025-03-31 |
| 2023-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $1.10M derived: sum of 2 quarters · filed 2025-01-17 | $1.10M 10-Q · filed 2025-01-17 | $1.10M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $743.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $743.00K 10-Q · filed 2024-08-13 | $743.00K derived: sum of 3 quarters · filed 2024-08-13 | $743.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-13 | $0.00 derived: sum of 2 quarters · filed 2024-05-13 | $0.00 derived: sum of 3 quarters · filed 2024-05-13 | $0.00 derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $0.00 derived: sum of 3 quarters · filed 2024-03-12 | $96.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $96.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $96.00K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $96.00K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $50.00K 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |